Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4D | Q6B0I6 | 4/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 5/20 | 0.38 |
| ▸ | JAK1 | P23458 | 5/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16444399 | 1.00 | KDM4D (0.45) | KDM4DKDM1AMAOBPARP1DRD2 | |
| SCHEMBL15289032 | 1.00 | KDM4D (0.45) | KDM4DKDM1AMAOBPARP1DRD2 | |
| SCHEMBL15270039 | 0.89 | KDM1A (0.46) | KDM4DKDM1AMAOBPARP1DRD2 | |
| SCHEMBL16456025 | 0.89 | KDM4D (0.46) | KDM4DKDM1AMAOBPARP1DRD2 | |
| SCHEMBL16444843 | 0.88 | KDM1A (0.53) | KDM1AMAOBDRD2EPHX2KMT2A | |
| SCHEMBL16444841 | 0.88 | KDM1A (0.53) | KDM1AMAOBDRD2EPHX2KMT2A | |
| SCHEMBL15289089 | 0.88 | KDM1A (0.53) | KDM1AMAOBDRD2EPHX2KMT2A | |
| SCHEMBL8181931 | 0.83 | ALDH1A1 (0.56) | DRD2KMT2AL3MBTL1 | |
| SCHEMBL15289028 | 0.82 | KDM4D (0.46) | KDM4DKDM1AMAOBPARP1DRD2 | |
| SCHEMBL17723343 | 0.79 | CTSS (0.47) | KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340549-B2 | Oxazolidinone compounds and derivatives thereof | AMGEN INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN INC. | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | TNKS1BP1, TNKS, TBKBP1 | KDM4D 1819/4885KDM1A 1093/4885MAOB 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.